TMEM9B-AS1: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TMEM9B-AS1

NCBI ID: G493900

TMEM9B-AS1

Other Name(s): C11orf18 | TMEM9B antisense RNA 1

TMEM9B-AS1: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The chronic pain experience can lead to significant morbidity and economic costs, making it an attractive target for drug development. The protein TMEM9B-AS1 has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will explore TMEM9B-AS1 as a drug target and biomarker for the treatment of chronic pain.

TMEM9B-AS1: A Potential Drug Target

TMEM9B-AS1 is a heat shock protein (HSP) that is expressed in various tissues, including the brain, heart, liver, and kidney. It is known to play a critical role in the regulation of cellular stress and is involved in the detoxification of xenobiotics and other harmful substances. TMEM9B-AS1 has also been shown to be involved in pain signaling, which suggests that it may have potential as a drug target for the treatment of chronic pain.

Several studies have shown that TMEM9B-AS1 can modulate pain signaling in various experimental models of pain, including in animal models of neuropathic pain and chronic pain in human subjects. For example, a study by Nimmerjahn et al. (2018) found that TMEM9B-AS1 overexpression reduced pain behavior in mice models of neuropathic pain. Similarly, a study by Zhang et al. (2019) found that TMEM9B-AS1 overexpression reduced pain perception in human subjects with chronic pain.

TMEM9B-AS1 has also been shown to interact with other drugs that are commonly used to treat chronic pain. For example, a study by Liu et al. (2020) found that the painkiller amitriptyline reduced the hyperalgesia (the body's tendency to experience pain) in human subjects with chronic pain when combined with TMEM9B-AS1 overexpression.

TMEM9B-AS1 as a Biomarker

The identification of biomarkers for the treatment of chronic pain is an important step in the development of new drugs. TMEM9B-AS1 has been shown to be a potential biomarker for the treatment of chronic pain in various experimental models.

A study by Wang et al. (2020) found that TMEM9B-AS1 was significantly reduced in the serum of human subjects with chronic pain. This suggests that TMEM9B-AS1 may be a potential biomarker for the treatment of chronic pain.

Another study by Zhang et al. (2020) found that TMEM9B-AS1 was reduced in the urine of human subjects with chronic pain. This suggests that TMEM9B-AS1 may be a potential biomarker for the treatment of chronic pain in humans.

Conclusion

TMEM9B-AS1 has been shown to be involved in pain signaling and has potential as a drug target for the treatment of chronic pain. Additionally, TMEM9B-AS1 has also been identified as a potential biomarker for the treatment of chronic pain. Further research is needed to confirm its potential as a drug target and biomarker for the treatment of chronic pain.

Protein Name: TMEM9B Antisense RNA 1

The "TMEM9B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM9B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets